Rating agencies expect U.S. spending bill to cut inflation, deficit over time
By Kanishka Singh
WASHINGTON, Aug 8 (Reuters) - A sweeping bill passed by the U.S. Senate on Sunday and intended to fight climate change, lower drug prices and raise some corporate taxes, will bring down inflation over the medium to long term and cut the deficit, rating agencies Moody's Investors service and Fitch Ratings told Reuters on Monday.
The legislation, known as the Inflation Reduction Act, however, will not bring down inflation "this coming year or next year," said Madhavi Bokil, senior vice president at Moody's Investors Service.
Charles Seville, senior director and Americas sovereigns co-head at Fitch, said that the legislation was disinflationary "but for all the rebranding of the legislation, the impacts on inflation are relatively small and will only really start to compound over the medium and long term as these provisions take effect."
"We do think that this act will have an impact (of cutting inflation) as it increases productivity," Bokil said, adding her horizon was two to three years.
The Senate on Sunday passed the $430 billion bill, a major victory for President Joe Biden, sending the measure to the House of Representatives for a vote, likely Friday. They are expected to pass it and send it to the White House for Biden's signature.
Republicans, arguing that the bill will not address inflation, have denounced it as a job-killing, left-wing spending wish list that could undermine growth when the economy is in danger of falling into recession.
Bokil said in the immediate short-term future, inflation was going to be tackled by the Federal Reserve as it raises rates.
Inflation expectations are a key dynamic being closely watched by Fed policymakers as they aggressively raise interest rates to contain price pressures running at four-decade highs.
While the short-term impact of the legislation on inflation will be modest, the bill still has the potential to bring down inflation expectations, Wendy Edelberg, a senior fellow in economic studies at Washington think tank the Brookings Institution, told Reuters in an email on Monday. Senate Democrats also said the act will cause a deficit reduction of $300 billion over the next decade while the U.S. Congressional Budget Office said the bill would decrease the federal deficit by a net $101.5 billion over that period. The CBO estimated in May that the 2022 federal budget deficit would be $1.036 trillion.
Asked about how the legislation would impact the budget deficit, Bokil said: "The savings from the Medicare side as well as the tax changes will more than offset the extra cost."
Seville also said that the bill will reduce deficits and help contain rising healthcare costs.
The legislation aims to reduce prescription drug costs by allowing Medicare, the government-run healthcare plan for the elderly and disabled, to negotiate prices on a limited number of drugs.
Edelberg also said the bill will lead to "greater corporate tax revenue than we otherwise would see", which will offset the cost and control the deficit.
Moody's said that the spending bill was complementary to another bill recently passed by Congress, which aimed to subsidize the U.S. semiconductor industry and boost efforts to make the United States more competitive with China.
"They move in the same direction, so the Chips Act will also help with alleviating some of the supply chain issues," Bokil added.
U.S. Senate approves bill to fight climate change, cut drug
costs in win for Biden
U.S. Senate's $430 billion climate bill to add tax on stock buybacks
U.S. climate deal has money for EVs, clean energy and even Big Oil
ANALYSIS-Democrats score big wins on climate, drugs with $430 billion U.S. Senate bill
Reporting by Kanishka Singh in Washington; Editing by Megan Davies and Lisa Shumaker
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.